ClinicalTrials.gg
RecruitingNCT05623904Updated Jan 31, 2023

Carotid Revascularization Versus Best Medical Treatment for Asymptomatic Carotid Stenosis

An interventional study of Carotid Revascularization and Medical Treatment in Carotid Artery Stenting, Carotid Endarterectomy and Best Medical Treatment, sponsored by Xuanwu Hospital, Beijing. Recruiting at 11 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,056
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing — 5 open to participants now, 6 under way, none of them phase 3. Carotid Stenosis · Xuanwu Hospital, Beijing.

Started
2022
with 2 others
No phase
5 of 11
2 open now
Registered
7th of 11
by date

Among the 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing, this one is one of 3 that started in 2022, is one of 5 with no phase, and was the 7th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

5 of the 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety of carotid artery stenting/carotid endarterectomy versus best medical treatment for asymptomatic carotid artery stenosis in Chinese population.

Read the detailed description

This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety of carotid artery stenting/carotid endarterectomy versus best medical treatment for asymptomatic carotid artery stenosis in Chinese population. The study will be conducted at 11 centers and is expected to enroll 1056 patients.

03

Conditions studied

  • Carotid Artery Stenting
  • Carotid Endarterectomy
  • Best Medical Treatment
  • Carotid Artery Stenosis Asymptomatic

Browse trials for

Keywords

  • Carotid Revascularization
  • Carotid Artery Stenting
  • Carotid Endarterectomy
  • Best Medical Treatment
  • Carotid Artery Stenosis Asymptomatic
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 40-80 years;
  2. Carotid artery stenosis 50%-90% (ultrasound, CT, or DSA);
  3. Asymptomatic carotid stenosis, that is, no , stroke, or other neurological symptoms in the past 6 months;
  4. Patients who could complete 12 months of follow-up;
  5. Patients who signed forms.

Exclusion criteria

Exclusion Criteria:

  1. Patients who had a , stroke, or other related neurological symptoms within the previous 6 months;
  2. Patients with spontaneous intracerebral hemorrhage in the past 12 months;
  3. Patients with large intracranial aneurysms (diameter> 5mm),and cannot be treated in advance or contemporaneous;
  4. Chronic total occlusion without obvious cerebral ischemia symptoms;
  5. Patients with neurologic disorder that caused transient or permanent neurological deficits and can not be identified with transient ischemic attack or stroke;
  6. Patients with severe dementia;
  7. Common carotid artery opening lesion;
  8. Severe intracranial stenosis in tandem;
  9. Carotid artery dissection;
  10. Carotid artery aneurysm;
  11. Myocardial infarction occurred within 30 days;
  12. It is known that two or more proximal or main coronary artery stenosis ≥70%, untreated or unable to recanalize;
  13. \<30% or (NYHA) functional class III or higher;Unstable angina,ie angina at resting state and changes;
  14. Patients with cardiac emboli sources, such as left ventricular aneurysm, intraluminal filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcific aortic stenosis, infective endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm, or left atrial myxoma;
  15. count \<5×104/μL, >1.5, Bleeding time > 1 min, or heparin-related thrombocytopenia;Patients to heparin and antiplatelet drugs;
  16. Patients with coagulation dysfunction.
  17. Poor control of diabetes, fasting blood glucose >22mmol/L and ketone body > +2;
  18. Malignant tumor or respiratory insufficiency, \< 5 years.
  19. Insufficiency of vital organs: forced expiratory volume at one second \< 30% (predicted); dialysis-dependent renal failure; intolerance to anesthesia;
  20. Currently waiting main organ transplants (ie heart, lung, liver, kidney), or are doing relevant evaluate;
  21. Need to perform other general anesthesia surgery during the same period;
  22. Pregnant or lactating women;
  23. Those who participated in clinical trials of other drugs or medical devices before the inclusion did not reach the end of the time limit;
  24. Investigators consider the patient inappropriate to participate in this clinical trial;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,056 participants (estimated)

Study arms

  • Active comparator
    Carotid Revascularization

    Carotid Artery Stenting/Carotid endarterectomy + Best Medical Treatment

    Procedure: Carotid Revascularization · Drug: Medical Treatment

  • Active comparator
    Medical Treatment

    Best Medical Treatment

    Drug: Medical Treatment

Interventions

  • ProcedureCarotid Revascularization

    Carotid Artery Stenting/Carotid Endarterectomy

  • DrugMedical Treatment

    Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up. In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.

06

What researchers measure

Primary outcomes

  1. Any Periprocedural Stroke, Myocardial Infarction, or Death During1 month Peri-procedural Period, and Postprocedural Ipsilateral Stroke 1 to 12-months.

    Composite of any periprocedural stroke (ipsilateral or contralateral; major or minor), myocardial infarction, or death during1 month peri-procedural period, and postprocedural ipsilateral stroke 1 to 12-months.

    Time frame: 0 to 12 months

Secondary outcomes

  1. Technical success rate

    Technical success was defined as final residual stenosis less than 30%, TIMI grade 3, and no dissection or thrombus after any endovascular treatment.

    Time frame: 1 day

  2. Rate of complications

    Rate of complications within 30 days, complications include:Cranial nerve and peripheral nerve injury, vascular injury, non cerebral hemorrhage, wound complications as neck incision or related to puncture site, and other (such as anesthesia) complications.

    Time frame: 30 days

  3. Incidence of myocardial infarction

    Incidence of myocardial infarction at 30 days follow up.

    Time frame: 30 days

  4. Incidence of ipsilateral stroke

    Incidence of ipsilateral stroke at 30 days follow up.

    Time frame: 30 days

  5. Incidence of death

    Incidence of death at 30 days follow up.

    Time frame: 30 days

  6. Carotid restenosis rate

    Carotid restenosis was defined as restenosis ≥50% after carotid revascularization, that is, peak systolic velocity ratio (PSVR) ≥2.0 on ultrasound examination.

    Time frame: 12 months

  7. Incidence of target lesion revascularization

    Target lesion revascularization (TLR) is defined as the re-percutaneous intervention or bypass grafting of the target lesion for restenosis or other complications of the target lesion. All TLR should be preclassified as clinically drived or non-clinically drived before the investigator performs angiography again.

    Time frame: 12 months

  8. Improvement in cognitive function

    Cognitive function was assessed by Montreal Cognitive Assessment Scale (MoCA) at 30 days follow up.

    Time frame: 30 days

  9. Improvement in cognitive function

    Cognitive function was assessed by Mini-mental State Examination (MMSE) at 30 days follow up.

    Time frame: 30 days

  10. Improvement in cognitive function

    Cognitive function was assessed by Montreal Cognitive Assessment Scale (MoCA) at 12 months follow up.

    Time frame: 12 months

  11. Improvement in cognitive function

    Cognitive function was assessed by Mini-mental State Examination (MMSE) at 12 months follow up.

    Time frame: 12 months

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2025, 38 months after the start.

Of 51 non-industry interventional studies with no phase under Carotid Stenosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's planned 38 months is above that.

Counting every sponsor, half of 62 studies reached it within 27 months; a quarter within 19 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2022
First posted
Nov 21, 2022
StartActual
Oct 14, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05623904
Collaborators
China-Japan Friendship Hospital, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Zhengzhou University, Changhai Hospital, Peking Union Medical College Hospital, Hebei General Hospital, The Second Hospital of Hebei Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, People's Hospital of Xinjiang Uygur Autonomous Region, Fifth Affiliated Hospital of Zhengzhou University
Responsible party
Sponsor
First posted
Nov 21, 2022
Start date
Oct 14, 2022
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 31, 2023

Study contacts

Yongquan Gu, Dr.
Contact
gu15901598209@aliyun.com
+8615901598209
Xixiang Gao, Dr.
Contact
vascsurgeon@163.com
+8613581674309
Yongquan Gu, Dr.
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion